Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline

Kyle LaHucik

Senior Reporter

Ironwood Pharmaceuticals agreed to buy Swiss biotech VectivBio in an all-cash deal with an estimated aggregate consideration of about $1 billion, extending the “

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Iron­wood to buy Vec­tivBio in $1B all-cash deal to ex­pand rare gas­troin­testi­nal pipeline

Senior Reporter

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline